P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives

Current Cancer Drug Targets

Volumn 13, Issue 3, 2013, Pages 326-346

  Binkhathlan, Ziyad ^a,b   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Chemotherapy; Drug delivery systems; Gene silencing; Multidrug resistance; P glycoprotein; P glycoprotein inhibitors

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A4; DEXVERAPAMIL; DOFEQUIDAR; DOXORUBICIN; EMOPAMIL; GLYCOPROTEIN P INHIBITOR; LANIQUIDAR; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; POLOXAMER; RIBOZYME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SPHINGOSINE KINASE; TARIQUIDAR; TESMILIFENE; TRABECTEDIN; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

APOPTOSIS; BREAST CANCER; CHEMOSENSITIZATION; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; GENE SILENCING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84876817977     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990076     Document Type: Review

References (249)

1. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990, 42 (3), 155-199.
2. Chin, K. V.; Pastan, I.; Gottesman, M. M. Function and regulation of the human multidrug resistance gene. Adv. Cancer Res. 1993, 60, 157-180.
3. Hiddemann, W.; Kern, W.; Schoch, C.; Fonatsch, C.; Heinecke, A.; Wormann, B.; Buchner, T. Management of acute myeloid leukemia in elderly patients. J. Clin. Oncol. 1999, 17 (11), 3569-3576.
4. Jamroziak, K.; Robak, T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 2004, 9 (2), 91-105.
5. Leighton, J. C., Jr.; Goldstein, L. J. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol. Oncol. Clin. North Am. 1995, 9 (2), 251-273.
6. Zhang, D.; Fan, D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert. Rev. Anticancer Ther. 2007, 7 (10), 1369-1378.
7. Nelson, D. A.; Tan, T. T.; Rabson, A. B.; Anderson, D.; Degenhardt, K.; White, E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 2004, 18 (17), 2095-2107.
8. Brizel, D. M.; Scully, S. P.; Harrelson, J. M.; Layfield, L. J.; Bean, J. M.; Prosnitz, L. R.; Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56 (5), 941-943.
9. Brown, J. M. Tumor hypoxia, drug resistance, and metastases. J. Natl. Cancer Inst. 1990, 82 (5), 338-339.
10. Harris, A. L. Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2 (1), 38-47.
11. Hockel, M.; Schlenger, K.; Hockel, S.; Vaupel, P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999, 59 (18), 4525-4528.
12. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41 (1), 31-39.
13. Shannon, A. M.; Bouchier-Hayes, D. J.; Condron, C. M.; Toomey, D. Tumour hypoxia, chemotherapeutic resistance and hypoxiarelated therapies. Cancer Treat. Rev. 2003, 29 (4), 297-307.
14. Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99 (19), 1441-1454.
15. Young, S. D.; Hill, R. P. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J. Natl Cancer Inst. 1990, 82 (5), 371-380.
16. Comerford, K. M.; Wallace, T. J.; Karhausen, J.; Louis, N. A.; Montalto, M. C.; Colgan, S. P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62 (12), 3387-3394.
17. Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34 (7), 592-602.
18. Yague, E.; Arance, A.; Kubitza, L.; O'Hare, M.; Jat, P.; Ogilvie, C. M.; Hart, I. R.; Higgins, C. F.; Raguz, S. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 2007, 67 (3), 1130-1137.
19. Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11 (4), 265-283.
20. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001, 42 (7), 1007-1017.
21. Albrecht, C.; Viturro, E. The ABCA subfamily--gene and protein structures, functions and associated hereditary diseases. Pflugers Arch. 2007, 453 (5), 581-589.
22. Mack, J. T.; Brown, C. B.; Tew, K. D. ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opin Ther. Targets 2008, 12 (4), 491-504.
23. Takahashi, K.; Kimura, Y.; Nagata, K.; Yamamoto, A.; Matsuo, M.; Ueda, K. ABC proteins: key molecules for lipid homeostasis. Med. Mol. Morphol. 2005, 38 (1), 2-12.
24. Herget, M.; Tampe, R. Intracellular peptide transporters in human--compartmentalization of the "peptidome". Pflugers Arch. 2007, 453 (5), 591-600.
25. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86 (3), 849-899.
26. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11 (7), 1156-1166.
27. Chen, Z. Q.; Dong, J.; Ishimura, A.; Daar, I.; Hinnebusch, A. G.; Dean, M. The essential vertebrate ABCE1 protein interacts with eukaryotic initiation factors. J. Biol. Chem. 2006, 281 (11), 7452-7457.
28. Kerr, I. D. Sequence analysis of twin ATP binding cassette proteins involved in translational control, antibiotic resistance, and ribonuclease L inhibition. Biochem. Biophys. Res. Commun. 2004, 315 (1), 166-173.
29. Bunting, K. D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002, 20 (1), 11-20.
30. Fletcher, J. I.; Haber, M.; Henderson, M. J.; Norris, M. D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10 (2), 147-156.
31. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 1976, 455 (1), 152-162.
32. Croop, J. M.; Guild, B. C.; Gros, P.; Housman, D. E. Genetics of multidrug resistance: relationship of a cloned gene to the complete multidrug resistant phenotype. Cancer Res. 1987, 47 (22), 5982-5988.
33. Gros, P.; Ben Neriah, Y. B.; Croop, J. M.; Housman, D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986, 323 (6090), 728-731.
34. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
35. Schinkel, A. H. The physiological function of drug-transporting Pglycoproteins. Semin. Cancer Biol. 1997, 8 (3), 161-170.
36. Lee, C. H.; Bradley, G.; Zhang, J. T.; Ling, V. Differential expression of P-glycoprotein genes in primary rat hepatocyte culture. J. Cell Physiol. 1993, 157 (2), 392-402.
37. Lin, J. H.; Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 2003, 42 (1), 59-98.
38. Ruetz, S.; Gros, P. Phosphatidylcholine translocase: A physiological role for the mdr2 gene. Cell. 1994, 77 (7), 1071-1081.
39. van Helvoort, A.; Smith, A. J.; Sprong, H.; Fritzsche, I.; Schinkel, A. H.; Borst, P.; van Meer, G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996, 87 (3), 507-517.
40. Chen, C. J.; Chin, J. E.; Ueda, K.; Clark, D. P.; Pastan, I.; Gottesman, M. M.; Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (Pglycoprotein) gene from multidrug-resistant human cells. Cell. 1986, 47 (3), 381-389.
41. Shustik, C.; Dalton, W.; Gros, P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol. Aspects Med. 1995, 16 (1), 1-78.
42. Sato, T.; Kodan, A.; Kimura, Y.; Ueda, K.; Nakatsu, T.; Kato, H. Functional role of the linker region in purified human Pglycoprotein. FEBS J. 2009, 276 (13), 3504-3516.
43. Rosenberg, M. F.; Callaghan, R.; Ford, R. C.; Higgins, C. F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem. 1997, 272 (16), 10685-10694.
44. Rosenberg, M. F.; Kamis, A. B.; Callaghan, R.; Higgins, C. F.; Ford, R. C. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J. Biol. Chem. 2003, 278 (10), 8294-8299.
45. McDevitt, C. A.; Shintre, C. A.; Grossmann, J. G.; Pollock, N. L.; Prince, S. M.; Callaghan, R.; Ford, R. C. Structural insights into Pglycoprotein (ABCB1) by small angle X-ray scattering and electron crystallography. FEBS Lett. 2008, 582 (19), 2950-2956.
46. O'Mara, M. L.; Tieleman, D. P. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett. 2007, 581 (22), 4217-4222.
47. Jin, M. S.; Oldham, M. L.; Zhang, Q.; Chen, J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490 (7421), 566-569.
48. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 2009, 323 (5922), 1718-1722.
49. Seelig, A.; Landwojtowicz, E. Structure-activity relationship of Pglycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 2000, 12 (1), 31-40.
50. Osterberg, T.; Norinder, U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur. J. Pharm. Sci. 2000, 10 (4), 295-303.
51. Altenberg, G. A.; Vanoye, C. G.; Horton, J. K.; Reuss, L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc. Natl. Acad. Sci. USA 1994, 91 (11), 4654-4657.
52. Raviv, Y.; Pollard, H. B.; Bruggemann, E. P.; Pastan, I.; Gottesman, M. M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 1990, 265 (7), 3975-3980.
53. Higgins, C. F.; Gottesman, M. M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 1992, 17 (1), 18-21.
54. Hitchcock, S. A. Structural modifications that alter the Pglycoprotein efflux properties of compounds. J. Med. Chem. 2012, 55 (11), 4877-4895.
55. Higgins, C. F.; Callaghan, R.; Linton, K. J.; Rosenberg, M. F.; Ford, R. C. Structure of the multidrug resistance P-glycoprotein. Semin. Cancer Biol. 1997, 8 (3), 135-142.
56. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 86 (2), 695-698.
57. Ho, R. H.; Kim, R. B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 2005, 78 (3), 260-277.
58. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 1987, 84 (21), 7735-7738.
59. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361-398.
60. Hsing, S.; Gatmaitan, Z.; Arias, I. M. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992, 102 (3), 879-885.
61. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and Pglycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13 (3), 129-134.
62. Benet, L. Z.; Cummins, C. L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 2001, 50 (Suppl 1), S3-11.
63. Zhang, Y.; Benet, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001, 40 (3), 159-168.
64. Cummins, C. L.; Mangravite, L. M.; Benet, L. Z. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm. Res. 2001, 18 (8), 1102-1109.
65. Synold, T. W.; Dussault, I.; Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7 (5), 584-590.
66. Kusuhara, H.; Suzuki, H.; Sugiyama, Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 1998, 87 (9), 1025-1040.
67. Matheny, C. J.; Lamb, M. W.; Brouwer, K. R.; Pollack, G. M. Pharmacokinetic and pharmacodynamic implications of Pglycoprotein modulation. Pharmacotherapy 2001, 21 (7), 778-796.
68. Ernest, S.; Rajaraman, S.; Megyesi, J.; Bello-Reuss, E. N. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1997, 77 (3), 284-289.
69. Okamura, N.; Hirai, M.; Tanigawara, Y.; Tanaka, K.; Yasuhara, M.; Ueda, K.; Komano, T.; Hori, R. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J. Pharmacol. Exp. Ther. 1993, 266 (3), 1614-1619.
70. Joo, F. Endothelial cells of the brain and other organ systems: some similarities and differences. Prog. Neurobiol. 1996, 48 (3), 255-273.
71. van Asperen, J.; Mayer, U.; van Tellingen, O.; Beijnen, J. H. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 1997, 86 (8), 881-884.
72. Drion, N.; Lemaire, M.; Lefauconnier, J. M.; Scherrmann, J. M. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem. 1996, 67 (4), 1688-1693.
73. Tsuji, A.; Terasaki, T.; Takabatake, Y.; Tenda, Y.; Tamai, I.; Yamashima, T.; Moritani, S.; Tsuruo, T.; Yamashita, J. Pglycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 1992, 51 (18), 1427-1437.
74. Goldstein, L. J.; Galski, H.; Fojo, A.; Willingham, M.; Lai, S. L.; Gazdar, A.; Pirker, R.; Green, A.; Crist, W.; Brodeur, G. M.; et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989, 81 (2), 116-124.
75. Sekine, I.; Shimizu, C.; Nishio, K.; Saijo, N.; Tamura, T. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int. J. Clin. Oncol. 2009, 14 (2), 112-119.
76. O'Driscoll, L.; Clynes, M. Biomarkers and multiple drug resistance in breast cancer. Curr. Cancer Drug Targets 2006, 6 (5), 365-384.
77. Trock, B. J.; Leonessa, F.; Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 1997, 89 (13), 917-931.
78. Goda, K.; Bacso, Z.; Szabo, G. Multidrug resistance through the spectacle of P-glycoprotein. Curr. Cancer Drug Targets 2009, 9 (3), 281-297.
79. Johnstone, R. W.; Ruefli, A. A.; Smyth, M. J. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci. 2000, 25 (1), 1-6.
80. Ruth, A. C.; Roninson, I. B. Effects of the multidrug transporter Pglycoprotein on cellular responses to ionizing radiation. Cancer Res. 2000, 60 (10), 2576-2578.
81. Tainton, K. M.; Smyth, M. J.; Jackson, J. T.; Tanner, J. E.; Cerruti, L.; Jane, S. M.; Darcy, P. K.; Johnstone, R. W. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004, 11 (9), 1028-1037.
82. Gouaze-Andersson, V.; Cabot, M. C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta. 2006, 1758 (12), 2096-2103.
83. Gouaze-Andersson, V.; Yu, J. Y.; Kreitenberg, A. J.; Bielawska, A.; Giuliano, A. E.; Cabot, M. C. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta. 2007, 1771 (12), 1407-1417.
84. Pallis, M.; Russell, N. P-glycoprotein plays a drug-effluxindependent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelinceramide apoptotic pathway. Blood 2000, 95 (9), 2897-2904.
85. Aouali, N.; Eddabra, L.; Macadre, J.; Morjani, H. Immunosuppressors and reversion of multidrug-resistance. Crit. Rev. Oncol. Hematol. 2005, 56 (1), 61-70.
86. Mimeault, M.; Hauke, R.; Batra, S. K. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther. 2008, 83 (5), 673-691.
87. Cabot, M. C.; Han, T. Y.; Giuliano, A. E. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett. 1998, 431 (2), 185-188.
88. Wang, H.; Giuliano, A. E.; Cabot, M. C. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol. Cancer Ther. 2002, 1 (9), 719-726.
89. Ford, J. M.; Hait, W. N. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993, 12 (1-3), 171-212.
90. Wang, S. W.; Monagle, J.; McNulty, C.; Putnam, D.; Chen, H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J. Pharm. Sci. 2004, 93 (11), 2755-2767.
91. Watanabe, T.; Nakayama, Y.; Naito, M.; Oh-hara, T.; Itoh, Y.; Tsuruo, T. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs. 1996, 7 (8), 825-832.
92. Lampidis, T. J.; Krishan, A.; Planas, L.; Tapiero, H. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv. 1986, 3 (4), 251-259.
93. Alaoui-Jamali, M. A.; Schecter, R. L.; Rustum, Y. M.; Centurioni, M. G.; Lehnert, S.; Batist, G. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. J. Pharmacol. Exp. Ther. 1993, 264 (3), 1299-1304.
94. Boesch, D.; Muller, K.; Pourtier-Manzanedo, A.; Loor, F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res. 1991, 196 (1), 26-32.
95. Krishna, R.; de Jong, G.; Mayer, L. D. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anticancer Res. 1997, 17 (5A), 3329-3334.
96. Dale, I. L.; Tuffley, W.; Callaghan, R.; Holmes, J. A.; Martin, K.; Luscombe, M.; Mistry, P.; Ryder, H.; Stewart, A. J.; Charlton, P.; Twentyman, P. R.; Bevan, P. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br. J. Cancer 1998, 78 (7), 885-892.
97. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996, 56 (18), 4171-4179.
98. Peck, R. A.; Hewett, J.; Harding, M. W.; Wang, Y. M.; Chaturvedi, P. R.; Bhatnagar, A.; Ziessman, H.; Atkins, F.; Hawkins, M. J. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 2001, 19 (12), 3130-3141.
99. Baguley, B. C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol. 2010, 46 (3), 308-316.
100. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 1999, 128 (2), 403-411.
101. Fox, E.; Bates, S. E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 2007, 7 (4), 447-459.
102. Abraham, J.; Edgerly, M.; Wilson, R.; Chen, C.; Rutt, A.; Bakke, S.; Robey, R.; Dwyer, A.; Goldspiel, B.; Balis, F.; Van Tellingen, O.; Bates, S. E.; Fojo, T. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin. Cancer Res. 2009, 15 (10), 3574-3582.
103. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theriault, R.; Booser, D.; Symmans, F. W.; Wong, F.; Blumenschein, G.; Fleming, D. R.; Rouzier, R.; Boniface, G.; Hortobagyi, G. N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104 (4), 682-691.
104. Burnett, A. K.; Milligan, D.; Goldstone, A.; Prentice, A.; McMullin, M. F.; Dennis, M.; Sellwood, E.; Pallis, M.; Russell, N.; Hills, R. K.; Wheatley, K. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br. J. Haematol. 2009, 145 (3), 318-332.
105. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 2011, 17 (3), 569-580.
106. Cripe, L. D.; Uno, H.; Paietta, E. M.; Litzow, M. R.; Ketterling, R. P.; Bennett, J. M.; Rowe, J. M.; Lazarus, H. M.; Luger, S.; Tallman, M. S. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebocontrolled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010, 116 (20), 4077-4085.
107. Reyno, L.; Seymour, L.; Tu, D.; Dent, S.; Gelmon, K.; Walley, B.; Pluzanska, A.; Gorbunova, V.; Garin, A.; Jassem, J.; Pienkowski, T.; Dancey, J.; Pearce, L.; MacNeil, M.; Marlin, S.; Lebwohl, D.; Voi, M.; Pritchard, K. Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J. Clin. Oncol. 2004, 22 (2), 269-276.
108. Oldham, R. K.; Reid, W. K.; Barnett, D. Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers. Cancer Biother. Radiopharm. 2000, 15 (2), 153-159.
109. Oldham, R. K.; Reid, W. K.; Preisler, H. D.; Barnett, D. A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. Cancer Biother. Radiopharm. 1998, 13 (2), 71-80.
110. Stein, C. A.; Cheng, Y. C. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science 1993, 261 (5124), 1004-1012.
111. Wagner, R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994, 372 (6504), 333-335.
112. Gao, P.; Zhou, G. Y.; Lei, D. P.; Zhang, X. F.; Li, L.; Xu, J. W.; Lin, X. Y. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells. Cytotherapy 2007, 9 (8), 795-801.
113. Dassow, H.; Lassner, D.; Remke, H.; Preiss, R. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules. Int. J. Clin. Pharmacol. Ther. 2000, 38 (4), 209-216.
114. Motomura, S.; Motoji, T.; Takanashi, M.; Wang, Y. H.; Shiozaki, H.; Sugawara, I.; Aikawa, E.; Tomida, A.; Tsuruo, T.; Kanda, N.; Mizoguchi, H. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998, 91 (9), 3163-3171.
115. Alahari, S. K.; Dean, N. M.; Fisher, M. H.; Delong, R.; Manoharan, M.; Tivel, K. L.; Juliano, R. L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1996, 50 (4), 808-819.
116. Quattrone, A.; Papucci, L.; Morganti, M.; Coronnello, M.; Mini, E.; Mazzei, T.; Colonna, F. P.; Garbesi, A.; Capaccioli, S. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol. Res. 1994, 6 (7), 311-320.
117. Rittierodt, M.; Tschernig, T.; Harada, K. Modulation of multidrugresistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 2004, 71 (3), 123-128.
118. Pakunlu, R. I.; Wang, Y.; Saad, M.; Khandare, J. J.; Starovoytov, V.; Minko, T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control Release 2006, 114 (2), 153-162.
119. Abbasi, M.; Lavasanifar, A.; Berthiaume, L. G.; Weinfeld, M.; Uludag, H. Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells. Cancer 2010, 116 (23), 5544-5554.
120. Bartsch, M.; Weeke-Klimp, A. H.; Hoenselaar, E. P.; Stuart, M. C.; Meijer, D. K.; Scherphof, G. L.; Kamps, J. A. Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo. J. Drug Target 2004, 12 (9-10), 613-621.
121. Bennett, C. F.; Chiang, M. Y.; Chan, H.; Shoemaker, J. E.; Mirabelli, C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1992, 41 (6), 1023-1033.
122. Lappalainen, K.; Urtti, A.; Soderling, E.; Jaaskelainen, I.; Syrjanen, K.; Syrjanen, S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim. Biophys. Acta. 1994, 1196 (2), 201-208.
123. Stuart, D. D.; Kao, G. Y.; Allen, T. M. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 2000, 7 (3), 466-475.
124. Fattal, E.; Bochot, A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int. J. Pharm. 2008, 364 (2), 237-248.
125. Ko, Y. T.; Bhattacharya, R.; Bickel, U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release. 2009, 133 (3), 230-237.
126. Vinogradov, S. V.; Batrakova, E. V.; Li, S.; Kabanov, A. V. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J. Drug Target. 2004, 12 (8), 517-526.
127. Astriab-Fisher, A.; Sergueev, D. S.; Fisher, M.; Shaw, B. R.; Juliano, R. L. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 2000, 60 (1), 83-90.
128. Da Ros, T.; Spalluto, G.; Prato, M.; Saison-Behmoaras, T.; Boutorine, A.; Cacciari, B. Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment. Curr. Med. Chem. 2005, 12 (1), 71-88.
129. Ren, Y.; Wang, Y.; Zhang, Y.; Wei, D. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo. Mol. Pharm. 2008, 5 (4), 579-587.
130. Zaug, A. J.; Cech, T. R. The intervening sequence RNA of Tetrahymena is an enzyme. Science 1986, 231 (4737), 470-475.
131. Haseloff, J.; Gerlach, W. L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988, 334 (6183), 585-591.
132. Herschlag, D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. Natl. Acad. Sci. USA 1991, 88 (16), 6921-6925.
133. Kobayashi, H.; Takemura, Y.; Wang, F. S.; Oka, T.; Ohnuma, T. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites. Int. J. Cancer 1999, 81 (6), 944-950.
134. Masuda, Y.; Kobayashi, H.; Holland, J. F.; Ohnuma, T. Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex. Cancer Chemother. Pharmacol. 1998, 42 (1), 9-16.
135. Gao, P.; Zhou, G. Y.; Zhang, Q. H.; Li, H.; Mu, K.; Yuan, Y. P.; Zhang, J.; Wang, B. H. Reversal MDR in breast carcinoma cells by transfection of ribozyme designed according the secondary structure of mdr1 mRNA. Chin. J. Physiol. 2006, 49 (2), 96-103.
136. Gao, P.; Zhou, G. Y.; Guo, L. L.; Zhang, Q. H.; Zhen, J. H.; Fang, A. J.; Lin, X. Y. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter. Cancer Lett. 2007, 256 (1), 81-89.
137. Gao, Z.; Gao, Z.; Fields, J. Z.; Boman, B. M. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells. Int. J. Cancer 1999, 82 (3), 346-352.
138. Gao, Z.; Gao, Z.; Liu, X.; Zhang, T. Selective reversal of drug resistance in drug-resistant lung adenocarcinoma cells by tumorspecific expression of mdrl ribozyme gene mediated by retrovirus. Sci. China C. Life Sci. 1997, 40 (2), 122-127.
139. Kaszubiak, A.; Holm, P. S.; Lage, H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int. J. Oncol. 2007, 31 (2), 419-430.
140. Palfner, K.; Kneba, M.; Hiddemann, W.; Bertram, J. Improvement of hammerhead ribozymes cleaving mdr-1 mRNA. Biol. Chem. Hoppe Seyler. 1995, 376 (5), 289-295.
141. Qia, S.; Wang, H.; Chen, X. Reversal of HCC drug resistance by using hammerhead ribozymes against multidrug resistance 1 gene. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2005, 25 (6), 662-664.
142. Rao, D. D.; Vorhies, J. S.; Senzer, N.; Nemunaitis, J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61 (9), 746-759.
143. Nieth, C.; Priebsch, A.; Stege, A.; Lage, H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003, 545 (2-3), 144-150.
144. Wu, H.; Hait, W. N.; Yang, J. M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003, 63 (7), 1515-1519.
145. Abbasi, M.; Lavasanifar, A.; Uluda, H. Recent attempts at RNAimediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med. Res. Rev. 2013, 33 (1), 33-53.
146. Chen, X. P.; Wang, Q.; Guan, J.; Huang, Z. Y.; Zhang, W. G.; Zhang, B. X. Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J. Gastroenterol. 2006, 12 (21), 3332-3337.
147. Duan, Z.; Brakora, K. A.; Seiden, M. V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 2004, 3 (7), 833-838.
148. Gan, H. Z.; Zhang, G. Z.; Zhao, J. S.; Zhang, F. C.; Bu, L. S.; Yang, S. J.; Piao, S. L.; Du, Z. W.; Gao, S.; Zheng, D. M. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. Chin. Med. J. (Engl). 2005, 118 (11), 893-902.
149. Lage, H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 2006, 7 (7), 813-821.
150. Li, L.; Xu, J.; Min, T.; Huang, W. Reversal of MDR1 genedependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA. Eur. J. Pharmacol. 2006, 536 (1-2), 93-97.
151. Materna, V.; Pleger, J.; Hoffmann, U.; Lage, H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol. Oncol. 2004, 94 (1), 152-160.
152. Miyagishi, M.; Matsumoto, S.; Akashi, H.; Kawasaki, H.; Fukao, T.; Fukuda, Y.; Sano, M.; Kato, Y.; Takagi, Y.; Tanaka, Y.; Warashina, M.; Kuwabara, T.; Sawata, S. Y.; Ikeda, Y.; Kawahara, S.; Sunil, K. C.; Wadhwa, R.; Taira, K. Chemistry-based RNA technologies: demonstration of usefulness of libraries of ribozymes and short hairpin RNAs (shRNAs). Nucleic Acids Symp. Ser. (Oxf). 2005, 49, 91-92.
153. Park, S. Y.; Kwak, W.; Thapa, N.; Jung, M. Y.; Nam, J. O.; So, I. S.; Kim, S. Y.; Yoo, J.; Lee, J.; Kim, I. S. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter. J. Nucl. Med. 2008, 49 (9), 1480-1488.
154. Pichler, A.; Zelcer, N.; Prior, J. L.; Kuil, A. J.; Piwnica-Worms, D. In vivo RNA interference-mediated ablation of MDR1 Pglycoprotein. Clin. Cancer Res. 2005, 11 (12), 4487-4494.
155. Shi, Z.; Liang, Y. J.; Chen, Z. S.; Wang, X. W.; Wang, X. H.; Ding, Y.; Chen, L. M.; Yang, X. P.; Fu, L. W. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector based RNA interference in vitro and in vivo. Cancer Biol. Ther. 2006, 5 (1), 39-47.
156. Stege, A.; Priebsch, A.; Nieth, C.; Lage, H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 2004, 11 (11), 699-706.
157. Stein, U.; Walther, W.; Stege, A.; Kaszubiak, A.; Fichtner, I.; Lage, H. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol. Ther. 2008, 16 (1), 178-186.
158. Xia, Z.; Zhu, Z.; Zhang, L.; Royal, C.; Liu, Z.; Chen, Q.; Adam, B. L. Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol. Rep. 2008, 20 (6), 1433-1439.
159. Xiao, L.; Gao, R.; Lu, S.; Ren, L.; Wang, Z. Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2006, 26 (6), 735-737.
160. Xu, D.; McCarty, D.; Fernandes, A.; Fisher, M.; Samulski, R. J.; Juliano, R. L. Delivery of MDR1 small interfering RNA by selfcomplementary recombinant adeno-associated virus vector. Mol. Ther. 2005, 11 (4), 523-530.
161. Ye, X.; Liu, T.; Gong, Y.; Zheng, B.; Meng, W.; Leng, Y. Lentivirus-mediated RNA interference reversing the drugresistance in MDR1 single-factor resistant cell line K562/MDR1. Leuk. Res. 2009, 33 (8), 1114-1119.
162. Zhang, X.; Li, J.; Qiu, Z.; Gao, P.; Wu, X.; Zhou, G. Cosuppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi). Cancer Biol. Ther. 2009, 8 (12), 1117-1121.
163. Xiong, X. B.; Uludag, H.; Lavasanifar, A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials 2010, 31 (22), 5886-5893.
164. Xiong, X. B.; Uludag, H.; Lavasanifar, A. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009, 30 (2), 242-253.
165. Vickers, T. A.; Koo, S.; Bennett, C. F.; Crooke, S. T.; Dean, N. M.; Baker, B. F. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 2003, 278 (9), 7108-7118.
166. Alahari, S. K.; DeLong, R.; Fisher, M. H.; Dean, N. M.; Viliet, P.; Juliano, R. L. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 1998, 286 (1), 419-428.
167. Bennett, C. F. Antisense oligonucleotides: is the glass half full or half empty? Biochem. Pharmacol. 1998, 55 (1), 9-19.
168. McManus, M. T.; Sharp, P. A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 2002, 3 (10), 737-747.
169. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6 (3), 686-695.
170. Haupenthal, J.; Baehr, C.; Zeuzem, S.; Piiper, A. RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. Int. J. Cancer 2007, 121 (1), 206-210.
171. Gilmore, I. R.; Fox, S. P.; Hollins, A. J.; Akhtar, S. Delivery strategies for siRNA-mediated gene silencing. Curr. Drug Deliv. 2006, 3 (2), 147-145.
172. Labialle, S.; Gayet, L.; Marthinet, E.; Rigal, D.; Baggetto, L. G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem. Pharmacol. 2002, 64 (5-6), 943-948.
173. Scotto, K. W. Transcriptional regulation of ABC drug transporters. Oncogene 2003, 22 (47), 7496-7511.
174. Scotto, K. W.; Johnson, R. A. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol. Interv. 2001, 1 (2), 117-125.
175. McCoy, C.; McGee, S. B.; Cornwell, M. M. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ. 1999, 10 (6), 377-386.
176. Bartsevich, V. V.; Juliano, R. L. Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. Mol. Pharmacol. 2000, 58 (1), 1-10.
177. Jin, S.; Gorfajn, B.; Faircloth, G.; Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA 2000, 97 (12), 6775-6779.
178. D'Incalci, M.; Jimeno, J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin. Investig. Drugs 2003, 12 (11), 1843-1853.
179. Jimeno, J.; Aracil, M.; Tercero, J. C. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J. Transl. Med. 2006, 4, 3.
180. Kanzaki, A.; Takebayashi, Y.; Ren, X. Q.; Miyashita, H.; Mori, S.; Akiyama, S.; Pommier, Y. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol. Cancer Ther. 2002, 1 (14), 1327-1334.
181. Martinez, N.; Sanchez-Beato, M.; Carnero, A.; Moneo, V.; Tercero, J. C.; Fernandez, I.; Navarrete, M.; Jimeno, J.; Piris, M. A. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol. Cancer Ther. 2005, 4 (5), 814-823.
182. Soares, D. G.; Escargueil, A. E.; Poindessous, V.; Sarasin, A.; de Gramont, A.; Bonatto, D.; Henriques, J. A.; Larsen, A. K. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl. Acad. Sci. USA 2007, 104 (32), 13062-13067.
183. Tavecchio, M.; Simone, M.; Erba, E.; Chiolo, I.; Liberi, G.; Foiani, M.; D'Incalci, M.; Damia, G. Role of homologous recombination in trabectedin-induced DNA damage. Eur. J. Cancer 2008, 44 (4), 609-618.
184. Nadali, F.; Pourfathollah, A. A.; Alimoghaddam, K.; Nikougoftar, M.; Rostami, S.; Dizaji, A.; Azizi, E.; Zomorodipour, A.; Ghavamzadeh, A. Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematology 2007, 12 (5), 393-401.
185. Kang, H.; DeLong, R.; Fisher, M. H.; Juliano, R. L. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 2005, 22 (12), 2099-2106.
186. Nagata, J.; Kijima, H.; Hatanaka, H.; Asai, S.; Miyachi, H.; Abe, Y.; Yamazaki, H.; Nakamura, M.; Watanabe, N.; Mine, T.; Kondo, T.; Scanlon, K. J.; Ueyama, Y. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int. J. Oncol. 2002, 21 (5), 1021-1026.
187. Celius, T.; Garberg, P.; Lundgren, B. Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. Biochem. Biophys. Res. Commun. 2004, 324 (1), 365-371.
188. Xia, Z.; Zhang, L.; Chen, Q.; Royal, C.; Yu, Z.; Liu, Z.; Adam, B. L. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol. Med. Report 2009, 2 (4), 579-584.
189. Peng, Z.; Xiao, Z.; Wang, Y.; Liu, P.; Cai, Y.; Lu, S.; Feng, W.; Han, Z. C. Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther. 2004, 11 (11), 707-712.
190. Logashenko, E. B.; Vladimirova, A. V.; Repkova, M. N.; Venyaminova, A. G.; Chernolovskaya, E. L.; Vlassov, V. V. Silencing of MDR 1 gene in cancer cells by siRNA. Nucleosides Nucleotides Nucleic Acids. 2004, 23 (6-7), 861-866.
191. Yague, E.; Higgins, C. F.; Raguz, S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther. 2004, 11 (14), 1170-1174.
192. Su, F.; Ouyang, N.; Zhu, P.; Ouyang, N.; Jia, W.; Gong, C.; Ma, X.; Xu, H.; Song, E. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem. Biophys. Res. Commun. 2005, 329 (3), 888-897.
193. Li, C. B.; Zhang, F.; Shi, Y. R.; Wei, X. Y.; Yang, Y.; Niu, R. F. [Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA]. Ai Zheng. 2004, 23 (12), 1605-1610.
194. Stierle, V.; Laigle, A.; Jolles, B. The reduction of P-glycoprotein expression by small interfering RNAs is improved in exponentially growing cells. Oligonucleotides. 2004, 14 (3), 191-198.
195. Xu, D.; Kang, H.; Fisher, M.; Juliano, R. L. Strategies for inhibition of MDR1 gene expression. Mol. Pharmacol. 2004, 66 (2), 268-275.
196. Xiao, H.; Wu, Z.; Shen, H.; Luo, A. L.; Yang, Y. F.; Li, X. B.; Zhu, D. Y. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin. Pharmacol. Toxicol. 2008, 103 (4), 342-348.
197. Xing, H.; Wang, S.; Weng, D.; Chen, G.; Yang, X.; Zhou, J.; Xu, G.; Lu, Y.; Ma, D. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol. Rep. 2007, 17 (1), 117-122.
198. Zhang, T.; Guan, M.; Jin, H. Y.; Lu, Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol. Oncol. 2005, 97 (2), 501-507.
199. Patil, Y. B.; Swaminathan, S. K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31 (2), 358-365.
200. Patutina, O. A.; Mironova, N. L.; Popova, N. A.; Kaledin, V. I.; Nikolin, V. P.; Vlassov, V. V.; Zenkova, M. A. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer 2010, 10, 204.
201. Hua, J.; Mutch, D. G.; Herzog, T. J. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol. Oncol. 2005, 98 (1), 31-38.
202. Abbasi, M.; Aliabadi, H. M.; Moase, E. H.; Lavasanifar, A.; Kaur, K.; Lai, R.; Doillon, C.; Uludag, H. siRNA-mediated downregulation of P-glycoprotein in a Xenograft tumor model in NODSCID mice. Pharm. Res. 2011, 28 (10), 2516-2529.
203. Perez, J.; Bardin, C.; Rigal, C.; Anthony, B.; Rousseau, R.; Dutour, A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 2011, 31 (9), 2813-2820.
204. Donmez, Y.; Gunduz, U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed. Pharmacother. 2011, 65 (2), 85-89.
205. Navarro, G.; Sawant, R. R.; Biswas, S.; Essex, S.; Tros de Ilarduya, C.; Torchilin, V. P. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond). 2012, 7 (1), 65-78.
206. Zhang, H.; Wang, J.; Cai, K.; Jiang, L.; Zhou, D.; Yang, C.; Chen, J.; Chen, D.; Dou, J. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. J. Cancer Res. Ther. 2012, 8 (2), 226-231.
207. Hao, Y. X.; He, Z. W.; Zhu, J. H.; Shen, Q.; Sun, J. Z.; Du, N.; Xiao, W. H. Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene. Chin. Med. J. (Engl). 2012, 125 (15), 2741-2745.
208. Riehm, H.; Biedler, J. L. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res. 1972, 32 (6), 1195-1200.
209. Mayer, L. D.; Shabbits, J. A. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev. 2001, 20 (1-2), 87-93.
210. Thierry, A. R.; Dritschilo, A.; Rahman, A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem. Biophys. Res. Commun. 1992, 187 (2), 1098-1105.
211. Sadava, D.; Coleman, A.; Kane, S. E. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J. Liposome Res. 2002, 12 (4), 301-309.
212. Warren, L.; Jardillier, J. C.; Malarska, A.; Akeli, M. G. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res. 1992, 52 (11), 3241-3245.
213. Riganti, C.; Voena, C.; Kopecka, J.; Corsetto, P. A.; Montorfano, G.; Enrico, E.; Costamagna, C.; Rizzo, A. M.; Ghigo, D.; Bosia, A. Liposome-Encapsulated Doxorubicin Reverses Drug Resistance by Inhibiting P-Glycoprotein in Human Cancer Cells. Mol. Pharm. 2011, 8 (3), 683-700.
214. Krieger, M. L.; Konold, A.; Wiese, M.; Jaehde, U.; Bendas, G. Targeted doxorubicin-liposomes as a tool to circumvent P-gpmediated resistance in ovarian carcinoma cells. Int. J. Clin. Pharmacol. Ther. 2010, 48 (7), 442-444.
215. Rivera, E.; Valero, V.; Esteva, F. J.; Syrewicz, L.; Cristofanilli, M.; Rahman, Z.; Booser, D. J.; Hortobagyi, G. N. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother. Pharmacol. 2002, 49 (4), 299-302.
216. Hu, Y. P.; Henry-Toulme, N.; Robert, J. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. Eur. J. Cancer 1995, 31A (3), 389-394.
217. Wang, Y.; Eksborg, S.; Lewensohn, R.; Lindberg, A.; Liliemark, E. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells. Anticancer Drugs 1999, 10 (10), 921-928.
218. Li, X.; Lu, W. L.; Liang, G. W.; Ruan, G. R.; Hong, H. Y.; Long, C.; Zhang, Y. T.; Liu, Y.; Wang, J. C.; Zhang, X.; Zhang, Q. Effect of stealthy liposomal topotecan plus amlodipine on the multidrugresistant leukaemia cells in vitro and xenograft in mice. Eur. J. Clin. Invest. 2006, 36 (6), 409-418.
219. Wang, J.; Goh, B.; Lu, W.; Zhang, Q.; Chang, A.; Liu, X. Y.; Tan, T. M.; Lee, H. In vitro cytotoxicity of Stealth liposomes coencapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 2005, 28 (5), 822-828.
220. Wu, J.; Lu, Y.; Lee, A.; Pan, X.; Yang, X.; Zhao, X.; Lee, R. J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm Sci. 2007, 10 (3), 350-357.
221. Alakhov, V.; Moskaleva, E.; Batrakova, E. V.; Kabanov, A. V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. 1996, 7 (2), 209-216.
222. Venne, A.; Li, S.; Mandeville, R.; Kabanov, A.; Alakhov, V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996, 56 (16), 3626-3629.
223. Alakhov, V.; Klinski, E.; Li, S.; Pietrzynski, G.; Venne, A.; Batrakova, E.; Bronitch, T.; Kabanov, A. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surfaces B: Biointerfaces 1999, 16 (1-4), 113-134.
224. Batrakova, E. V.; Dorodnych, T. Y.; Klinskii, E. Y.; Kliushnenkova, E. N.; Shemchukova, O. B.; Goncharova, O. N.; Arjakov, S. A.; Alakhov, V. Y.; Kabanov, A. V. Anthracycline antibiotics noncovalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer 1996, 74 (10), 1545-1552.
225. Batrakova, E. V.; Li, S.; Brynskikh, A. M.; Sharma, A. K.; Li, Y.; Boska, M.; Gong, N.; Mosley, R. L.; Alakhov, V. Y.; Gendelman, H. E.; Kabanov, A. V. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J. Control Rel. 2010, 143 (3), 290-301.
226. Valle, J. W.; Armstrong, A.; Newman, C.; Alakhov, V.; Pietrzynski, G.; Brewer, J.; Campbell, S.; Corrie, P.; Rowinsky, E. K.; Ranson, M. A phase 2 study of SP1049C, doxorubicin in Pglycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 2011, 29 (5), 1029-1037.
227. Yokoyama, M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin. Drug Deliv. 2010, 7 (2), 145-158.
228. Valle, J. W.; Lawrance, J.; Brewer, J.; Clayton, A.; Corrie, P.; Alakhov, V.; Ranson, M. A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus. J. Clin. Oncol. 2004, 22 (14S), 4195.
229. Zastre, J.; Jackson, J.; Bajwa, M.; Liggins, R.; Iqbal, F.; Burt, H. Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers. Eur. J. Pharm. Biopharm. 2002, 54 (3), 299-309.
230. Elamanchili, P.; McEachern, C.; Burt, H. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J. Pharm. Sci. 2009, 98 (3), 945-958.
231. Batrakova, E. V.; Li, S.; Alakhov, V. Y.; Miller, D. W.; Kabanov, A. V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 2003, 304 (2), 845-854.
232. Zastre, J. A.; Jackson, J. K.; Wong, W.; Burt, H. M. P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity. Mol. Pharm. 2008, 5 (4), 643-653.
233. Batrakova, E.; Lee, S.; Li, S.; Venne, A.; Alakhov, V.; Kabanov, A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 1999, 16 (9), 1373-1379.
234. Miller, D. W.; Batrakova, E. V.; Waltner, T. O.; Alakhov, V.; Kabanov, A. V. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug. Chem. 1997, 8 (5), 649-657.
235. Astier, A.; Doat, B.; Ferrer, M. J.; Benoit, G.; Fleury, J.; Rolland, A.; Leverge, R. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res. 1988, 48 (7), 1835-1841.
236. Omelyanenko, V.; Kopeckova, P.; Gentry, C.; Kopecek, J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control Rel. 1998, 53 (1-3), 25-37.
237. Hu, C. M.; Zhang, L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab. 2009, 10 (8), 836-841.
238. de Verdiere, A. C.; Dubernet, C.; Nemati, F.; Soma, E.; Appel, M.; Ferte, J.; Bernard, S.; Puisieux, F.; Couvreur, P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 1997, 76 (2), 198-205.
239. Pepin, X.; Attali, L.; Domrault, C.; Gallet, S.; Metreau, J. M.; Reault, Y.; Cardot, P. J.; Imalalen, M.; Dubernet, C.; Soma, E.; Couvreur, P. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B. Biomed. Sci. Appl. 1997, 702 (1-2), 181-191.
240. Kopecek, J.; Kopeckova, P.; Minko, T.; Lu, Z. HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50 (1), 61-81.
241. Dong, X.; Mumper, R. J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond). 2010, 5 (4), 597-615.
242. Shukla, S.; Wu, C. P.; Ambudkar, S. V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert. Opin. Drug Metab. Toxicol. 2008, 4 (2), 205-223.
243. Advani, R.; Lum, B. L.; Fisher, G. A.; Halsey, J.; Chin, D. L.; Jacobs, C. D.; Sikic, B. I. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann. Oncol. 2005, 16 (12), 1968-1973.
244. Fracasso, P. M.; Blum, K. A.; Ma, M. K.; Tan, B. R.; Wright, L. P.; Goodner, S. A.; Fears, C. L.; Hou, W.; Arquette, M. A.; Picus, J.; Denes, A.; Mortimer, J. E.; Ratner, L.; Ivy, S. P.; McLeod, H. L. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br. J. Cancer 2005, 93 (1), 46-53.
245. Krishna, R.; Mayer, L. D. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 1997, 57 (23), 5246-5253.
246. Krishna, R.; McIntosh, N.; Riggs, K. W.; Mayer, L. D. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin. Cancer Res. 1999, 5 (10), 2939-2947.
247. Binkhathlan, Z.; Shayeganpour, A.; Brocks, D. R.; Lavasanifar, A. Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. Eur. J. Pharm. Biopharm. 2012, 81 (1), 142-148.
248. Soma, C. E.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials. 2000, 21 (1), 1-7.
249. Patel, N. R.; Rathi, A.; Mongayt, D.; Torchilin, V. P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416 (1), 296-299.